Kim Anna Reiss, MD, University of Pennsylvania, Philadelphia, PA, discusses the implementing PM in pancreatic cancer. BRCA and PALB2 variants are targets currently under investigation for ATM and other germline variants. In the somatic setting, targets actively in trial or under investigation include NTRK fusions, NRG1 fusions, BRCA, PALB2, BRAF and KRASG12C, highlighting the importance of somatic sequencing and using a set of somatic panels that capture the range of possible targets. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.